The participation of p53 and bcl-2 proteins in gastric carcinomas associated with Helicobacter pylori and/or Epstein-Barr Virus (EBV)

• Autorzy: Szkaradkiewicz A. , Karpinski T.M. , Majewski J. , Malinowska K. , Goslinska-Kuzniarek O. , Linke K.
• Języki publikacji: EN

Abstrakty

EN

In the presented studies p53 and bcl-2 proteins expression were evaluated in samples of gastric carcinomas in patients with Helicobacter pylori or EBV or without H. pylori/EBV infection. The studies were conducted on 64 adult patients with gastric adenocarcinomas: 16 patients with H. pylori (cagA+)-positivity (group 1), 14 with EBV-positive tumours (group 2), 12 with H. pylori/EBV-positive tumours (group 3) and 22 patients with H. pylori/EBV-negative tumours (group 4). H. pylori presence in gastric tumour specimens was detected using Giemsa staining and bacterial culture technique. Moreover, cagA gene was detected using PCR. EBV infection was detected based on EBER presence in the tissue by RNA in situ hybridization. Expressions of p53 and bcl-2 proteins were analysed using immunohistochemistry. Expression of p53 was noted in 14 (84%) patients from group 1, 8 (57%) patients from group 2, 7 (58%) patients from group 3, and 19 (86%) patients from group 4, whereas expression of bcl-2 was noted in 12 (75%) patients from group 1, in 10 (71%) patients from group 2, 9 (75%) patients from group 3, and 6 (27%) patients from group 4. The obtained results allow the conclusion, that H. pylori (cagA+)-associated development of the gastric adenocarcinoma is determined by abnormalities in the p53 protein function and overexpression of anti-apoptotic bcl-2 protein, whereas EBV-associated adenocarcinomas seem to be related with apoptosis resistance associated with bcl-2 overexpression.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2015
• Tom: 64
• Numer: 3
• Opis fizyczny: p.211-216,fig.,ref.

Twórcy

autor

Szkaradkiewicz A.

• Department of Medical Microbiology, University of Medical Sciences in Poznan, Poznan, Poland

autor

Karpinski T.M.

• Department of Medical Microbiology, University of Medical Sciences in Poznan, Poznan, Poland

autor

Majewski J.

• Department of Clinical Pathomorphology, University of Medical Sciences in Poznan, Poznan, Poland

autor

Malinowska K.

• Department of Medical Microbiology, University of Medical Sciences in Poznan, Poznan, Poland

autor

Goslinska-Kuzniarek O.

• Department of Medical Microbiology, University of Medical Sciences in Poznan, Poznan, Poland

autor

Linke K.

• Department of Gastroenterology, Human Nutrition and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland

Bibliografia

• Bartchewsky W.Jr., M.R. Martini, A.C. Squassoni, M.C. Alvarez, M.S. Ladeira, D.M. Salvatore, M.A. Trevisan, J.Jr. Pedrazzoli and M.L. Ribeiro. 2010. Effects of Helicobacter pylori infection on the expressions of Bax and Bcl-2 in patients with chronic gastritis and gastric cancer. Dig. Dis. Sci. 55(1): 111–116.
• Berloco P., F. Russo, F. Cariola, M. Gentile, P. Giorgio, M.L. Caruso, A.M. Valentini, G. Di Matteo and A. Di Leo. 2003. Low presence of p53 abnormalities in H. pylori-infected gastric mucosa and in gastric adenocarcinoma. J. Gastroenterol. 38(1): 28–36.
• Bollig-Fischer A., M. Dziubinski, A. Boyer, R. Haddad, C.N. Giroux and S.P. Ethier. 2010. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 70(20): 7862–7873.
• Carcas LP. 2014. Gastric cancer review. J. Carcinog. 13: 14.
• Chen J.N., D. He, F. Tang and C.K. Shao. 2012. Epstein-Barr virus-associated gastric carcinoma: a newly defined entity. J. Clin. Gastroenterol. 46(4): 262–271.
• Czabotar P.E., G. Lessene, A. Strasser and J.M. Adams. 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15(1): 49–63.
• Czopek, J. P., M., Stojak, A., Bińczak, T., Popiela, J., Kulig, Z., Rudzki, and J. Stachura. 2003. EBV-positive gastric carcinomas in Poland. Pol. J. Pathol. 54(2): 123–128.
• Fu Q., C. He and Z.R. Mao. 2013. Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells. J. Zhejiang Univ. Sci. B 14(1): 8–24.
• Gravalos C. and A. Jimeno. 2008. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 19(9): 1523–1529.
• Helicobacter and Cancer Collaborative Group. 2001. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49(3): 347–353.
• Iizasa H., A. Nanbo, J. Nishikawa, M. Jinushi and H. Yoshiyama. 2012. Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses 4(12): 3420–3439.
• International Agency for Research on Cancer. 1994. Schistosomes, liver flukes and Helicobacter pylori. Evaluation of carcinogenic risks to humans. IARC Monograph Evaluating Carcinogenic Risks to Humans 61: 177–240.
• Ishii H., G. Gobé, Y. Kawakubo, Y. Sato and Y. Ebihara. 2001. Interrelationship between Epstein-Barr virus infection in gastric carcinomas and the expression of apoptosis-associated proteins. Histopathol. 38(2): 111–119.
• Ishii H.H., G.C. Gobe, J. Yoneyama, M. Mukaide and Y. Ebihara. 2004. Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas. J. Clin. Pathol. 57(12): 1306–1311.
• Izadi M. and S. Taheri. 2010. Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: report from the PTLD. Ann. Transplant. 15(4): 102–109.
• Konturek P.C., J. Kania, J.W. Konturek, A. Nikiforuk, S.J. Konturek and E.G. Hahn. 2003. H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis. Med. Sci. Mon. 9(7): SR53–66.
• Kountouras J., C. Zavos, D. Chatzopoulos and P. Katsinelos. 2008. New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J. Surg. Res. 146(1): 149–158.
• Kume T., K. Oshima, T. Shinohara, H. Takeo, Y. Yamashita, T. Shirakusa and M. Kikuchi. 1999. Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma. Histopathol. 34(6): 502–509.
• Kuniyasu H., W. Yasui, H. Yokozaki and E. Tahara. 2000. Helicobacter pylori infection and carcinogenesis of the stomach. Langenbecks Arch. Surg. 385(2): 69–74.
• Lee J.Y. and N. Kim. 2015. Diagnosis of Helicobacter pylori by invasive test: histology. Ann. Transl. Med. 3(1): 10.
• Lima V.P., M.A. de Lima, A.R. André, M.V. Ferreira, M.A.Barros and S.H. Rabenhorst. 2008. H. pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression. World J. Gastroenterol. 14(6): 884–891.
• Lin J.H., C.H. Tsai, J.S. Chu, J.Y. Chen, K. Takada and J.Y. Shew. 2007. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. J. Virol. 81(11): 5705–5713.
• Matsubara Y., H. Yanai, K. Ishiguro, S. Ryozawa, Y. Okazaki, N. Matsui and K. Okita. 2004. Clinical interpretation of the histological typing of gastric cancer using endoscopic forceps biopsy. Hepatogastroenterol. 51(55): 285–288.
• Matsumoto A., H. Isomoto, M. Nakayama, J. Hisatsune, Y. Nishi, Y. Nakashima, K. Matsushima, H. Kurazono, K. Nakao, T. Hirayama and S. Kohno. 2011. Helicobacter pylori VacA reduces the cellular expression of STAT3 and pro-survival Bcl-2 family proteins, Bcl-2 and Bcl-XL, leading to apoptosis in gastric epithelial cells. Dig. Dis. Sci. 56(4): 999–1006.
• Meng W.D., R.X. Chu, B.Z. Wang, L.P. Wang, L.L. Ma and L.X. Wang. 2013. Helicobacter pylori infection and expressions of apoptosis-related proteins p53, ASPP2 and iASPP in gastric cancer and precancerous lesions. Pathologie Biologie (Paris) 61(5): 199–202.
• Mérino D. and P. Bouillet. 2009. The Bcl-2 family in autoimmune and degenerative disorders. Apoptosis 14(4): 570–583.
• Moldoveanu T., A.V. Follis, R.W. Kriwacki and D.R. Green. 2014. Many players in BCL-2 family affairs. Trends Biochem. Sci. 39(3): 101–111.
• Murray P.G. and L.S. Young. 2002. The role of the Epstein-Barr virus in human disease. Front. Biosci. 7: d519–540.
• Nasierowska-Guttmejer A., L. Trzeciak, M.P. Nowacki and J. Ostrowski. 2000. p53 protein accumulation and p53 gene mutation in colorectal cancer. Pathol. Oncol. Res. 6(4): 275–279.
• Niedobitek G. and H. Herbst. 2006. In situ detection of Epstein-Barr virus and phenotype determination of EBV-infected cells. Methods Mol. Biol. 326: 115–137.
• Oldani A., M. Cormont, V. Hofman, V. Chiozzi, O. Oregioni, A. Canonici, A. Sciullo, P. Sommi, A. Fabbri, V. Ricci and P. Boquet. 2009. Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells. PLoS Pathogens 5(10): e1000603.
• Ozaki T. and A. Nakagawara. 2011. p53: the attractive tumor suppressor in the cancer research field. J. Biomed. Biotechnol. 2011: 603925.
• Palli D., G. Masala, G. Del Giudice, M. Plebani, D. Basso, D. Berti, M.E. Numans, M. Ceroti, P.H. Peeters, H.B. Bueno de Mesquita et al. 2007. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int. J. Cancer 120(4): 859–867.
• Petit B., K. Leroy, P. Kanavaros, M.L. Boulland, M. Druet-Cabanac, C. Haioun, D. Bordessoule and P. Gaulard. 2001. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. Human Pathol. 32(2): 196–204.
• Shibata A., T.A. Longacre, B. Puligandla, J. Parsonnet and L.A. Habel. 2001. Histological classification of gastric adenocarcinoma for epidemiological research: concordance between pathologists. Cancer Epidemiol. Biomarkers Prev. 10(1): 75–78.
• Shim J.H., J.H. Yoon, S.S. Choi, H. Ashktorab, D.T. Smoot, K.Y. Song, S.W. Nam, J.Y. Lee, C.H. Park and W.S. Park. 2014. The effect of Helicobacter pylori CagA on the HER-2 copy number and expression in gastric cancer. Gene 546(2): 288–296.
• Sivachandran N., C.W. Dawson, L.S. Young, F.F. Liu, J. Middeldorp and L. Frappier. 2012. Contributions of the Epstein-Barr virus EBNA1 protein to gastric carcinoma. J. Virol. 86(1): 60–68.
• Suriani R., M. Colozza, E. Cardesi, D. Mazzucco, M. Marino, S. Grosso, S. Sanseverinati, I. Venturini, A. Borghi and M.L. Zeneroli. 2008. CagA and VacA Helicobacter pylori antibodies in gastric cancer. Can. J. Gastroenterol. 22(3): 255–258.
• Szkaradkiewicz A., T.M. Karpiński, M. Drews, M. Borejsza-Wysocki, P. Majewski and E. Andrzejewska. 2010. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J. Biomed. Biotechnol. 2010: 901564.
• Szkaradkiewicz A., W. Majewski, M. Wal, M. Czyzak, P. Majewski, J. Bierła and A. Kuch. 2006. Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res. 118(1–2): 115–119.
• Targa A.C., A.C. César, P.M. Cury and A.E. Silva. 2007. Apoptosis in different gastric lesions and gastric cancer: relationship with Helicobacter pylori, overexpression of p53 and aneuploidy. Gen. Mol. Res. 6(3): 554–565.
• Thompson M.P. and R. Kurzrock. 2004. Epstein-Barr virus and cancer. Clin. Cancer Res. 10(3): 803–821.
• Vermeulen K., Z.N. Berneman and D.R. Van Bockstaele. 2003. Cell cycle and apoptosis. Cell Prolifer. 36(3): 165–175.
• Wang Y., B. Luo, L.P. Yan, B.H. Huang and P. Zhao. 2005. Relationship between Epstein-Barr virus-encoded proteins with cell proliferation, apoptosis, and apoptosis-related proteins in gastric carcinoma. World J. Gastroenterol. 11(21): 3234–3239.
• Wong H.L., X. Wang, R.C. Chang, D.Y. Jin, H. Feng, Q. Wang, K.W. Lo, D. Huang, P.W. Yuen, K. Takada and others. 2005. Stable expression of EBERs in immortalized nasopharyngeal epithelial cells confers resistance to apoptotic stress. Mol. Carcinogenesis 44(2): 92–101.
• Wu M.S., C.T. Shun, C.C. Wu, T.Y. Hsu, M.T. Lin, M.C. Chang, H.P. Wang and J.T. Lin. 2000. Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterol. 118(6): 1031–1038.
• Zimber-Strobl U., B. Kempkes, G. Marschall, R. Zeidler, C. Van Kooten, J. Banchereau, G.W. Bornkamm and W. Hammerschmidt. 1996. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15(24): 7070–7078.